Chen, Y.-W., Tucker, M. D., Brown, L. C., Yasin, H. A., Ancell, K. K., Armstrong, A. J., … Zhang, T. (2022). Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Chen, Yu-Wei, Matthew D. Tucker, Landon Carter Brown, Hesham Abdallah Yasin, Kristin Kathleen Ancell, Andrew J. Armstrong, Katy Beckermann, et al. “Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Chen Y-W, Tucker MD, Brown LC, Yasin HA, Ancell KK, Armstrong AJ, et al. Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC). In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Chen, Yu-Wei, et al. “Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Chen Y-W, Tucker MD, Brown LC, Yasin HA, Ancell KK, Armstrong AJ, Beckermann K, Davis NB, Harrison MR, Kaiser E, McAlister R, Schaffer K, Wallace D, George DJ, Rathmell WK, Rini BI, Zhang T. Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC). JOURNAL OF CLINICAL ONCOLOGY. 2022.